Abeona Therapeutics Inc.
LSE: 0H7R.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Vishwas Seshadri
- Employees
- 136
- Headquarters
- Cleveland, United States
- IPO year
- 2018
- Market cap
- $283.4M
- Website
- https://www.abeonatherapeutics.com
Loading 0H7R…
Loading profile data…Frequently asked questions about 0H7R
What does Abeona Therapeutics Inc. (0H7R.L) do?
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...
Where does 0H7R.L trade?
Abeona Therapeutics Inc. (0H7R.L) trades on the London Stock Exchange.
What sector is 0H7R.L in?
Abeona Therapeutics Inc. (0H7R.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Abeona Therapeutics Inc.?
Vishwas Seshadri is the chief executive officer of Abeona Therapeutics Inc. (0H7R.L).
Where is Abeona Therapeutics Inc. headquartered?
Abeona Therapeutics Inc. is headquartered in United States.
Does 0H7R.L pay a dividend?
Abeona Therapeutics Inc. (0H7R.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0H7R.L go public?
Abeona Therapeutics Inc. (0H7R.L) completed its initial public offering in 2018.